DLBCL Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Dr Neelapu talks about early findings from the ALPHA study which suggest that ALLO-501 and ALLO-647 are safe and may be effective in LBCL.
View More
Nilanjan Ghosh, MD, reviews results from a pilot study of lisocabtagene maraleucel for the treatment of relapsed large cell lymphomas.
View More
Dr Torka talks about the outcomes of patients with limited-stage, aggressive large B-cell lymphoma and high-risk cytogenetics.
View More
Sarah Rutherford, MD, discusses how postinduction bone marrow biopsy histology minimally affects radiographically-defined responses in patients with FL and DLBCL.
View More
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
View More
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, discusses results from the phase 1 Alexander study, which evaluated AUTO3 plus pembrolizumab in relapsed/refractory DLBCL.
View More
John Kuruvilla, MD, FRCPC, discusses the results from the phase 3 KEYNOTE‑204 trial, which compared pembrolizumab against brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma.
View More
Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
View More
Joseph Connors, MD, discusses the best choices for treating patients with advanced stage lymphoma.
View More